A similar finding has been previously reported in a pooled analysis of phase-2 and phase-3 RCTs only in patients with diabetes in whom the changes of urinary albumin-creatinine ratio after 24 weeks of dapagliflozin were of the same magnitude in patients whether receiving RAS inhibitors or not [33]. This evidence concerns the gene ALB and diabetes mellitus.